Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Nimotuzumab + Vinorelbine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Nimotuzumab | Theraloc|hR3 | EGFR Antibody 60 | Nimotuzumab is a humanized anti-EGFR antibody that blocks EGFR signaling, resulting in anti-tumor activity (PMID: 25842083, PMID: 32588692, PMID: 32021306). | |
Vinorelbine | Navelbine | Vinorelbin | Antimicrotubule Agent 14 | Navelbine (vinorelbine) is a tubulin binding alkaloid that inhibits tubulin polymerization, thus inhibiting spindle formation, leading to apoptosis (NCI Drug Dictionary). Navelbine (vinorelbine) is approved for use in NSCLC (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03620032 | Phase II | Nimotuzumab + Vinorelbine | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses (DIPG) | Active, not recruiting | ITA | 0 |